This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants with Adverse Events Reported During Safety Evaluations
Timeframe: Up to Day 44
Maximum Plasma Concentration (Cmax) of ABBV-722
Timeframe: Up to Day 21
Time to Cmax (Tmax) of ABBV-722
Timeframe: Up to Day 21
For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUCt) of ABBV-722
Timeframe: Up to Day 8
For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf) of ABBV-722
Timeframe: Up to Day 8
For Part 3: Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-722
Timeframe: Up to Day 21
For Part 3: AUC from Time 0 to the End of Dosing Interval (AUCtau) Following the First and Last Doses of ABBV-722
Timeframe: Up to Day 21
Terminal Phase Elimination Rate Constant (Beta) of ABBV-722
Timeframe: Up to Day 21
Terminal Phase Elimination Half-Life (t1/2) of ABBV-722
Timeframe: Up to Day 21
Dose Normalized Cmax
Timeframe: Up to Day 21
Dose Normalized AUCs
Timeframe: Up to Day 21